{"result": "(\"entity\"<|>HIPO_PARATIROIDISMO<|>EVENT<|>Hipoparatiroidismo is a medical condition that can occur as a complication of various treatments and diseases, including the ablation of the thyroid gland with radioactive iodine.)\n##\n(\"entity\"<|>ENFERMEDAD DE GRAVES<|>EVENT<|>Enfermedad de Graves is an autoimmune disorder that affects the thyroid, leading to hyperthyroidism and potentially requiring treatment with radioactive iodine.)\n##\n(\"entity\"<|>GLUCOCORTICOIDES<|>EVENT<|>Glucocorticoides are a class of corticosteroids that can lead to osteoporosis and other complications when used long-term.)\n##\n(\"entity\"<|>ENFERMEDAD DE WILSON<|>EVENT<|>Enfermedad de Wilson is a genetic disorder that leads to excessive copper accumulation in the body, which can affect parathyroid function.)\n##\n(\"entity\"<|>HEMOCROMATOSIS<|>EVENT<|>Hemocromatosis is a condition of iron overload that can lead to dysfunction of the parathyroid glands.)\n##\n(\"entity\"<|>TALASEMIA<|>EVENT<|>Talasemia is a blood disorder that can lead to iron overload due to frequent blood transfusions, affecting parathyroid function.)\n##\n(\"entity\"<|>FRATURA<|>EVENT<|>Fractura refers to a break in the bone, which can be a risk associated with osteoporosis and glucocorticoid use.)\n##\n(\"entity\"<|>DMO<|>EVENT<|>DMO, or densitometría ósea, is a test used to measure bone density and assess the risk of fractures, particularly in patients with osteoporosis.)\n##\n(\"entity\"<|>BISFOSFONATOS<|>EVENT<|>Bisfosfonatos are medications used to treat osteoporosis and reduce the risk of fractures in at-risk patients.)\n##\n(\"relationship\"<|>HIPO_PARATIROIDISMO<|>GLUCOCORTICOIDES<|>Hipoparatiroidismo can be a rare complication of glucocorticoid treatment.<|>6)\n##\n(\"relationship\"<|>ENFERMEDAD DE GRAVES<|>HIPO_PARATIROIDISMO<|>Hipoparatiroidismo can occur as a complication of thyroid ablation in patients with Enfermedad de Graves.<|>6)\n##\n(\"relationship\"<|>HEMOCROMATOSIS<|>HIPO_PARATIROIDISMO<|>Hipoparatiroidismo can be caused by infiltrative diseases like hemocromatosis affecting the parathyroid glands.<|>6)\n##\n(\"relationship\"<|>TALASEMIA<|>HIPO_PARATIROIDISMO<|>Hipoparatiroidismo can occur in patients with talasemia who have received multiple blood transfusions.<|>6)\n##\n(\"relationship\"<|>ENFERMEDAD DE WILSON<|>HIPO_PARATIROIDISMO<|>Hipoparatiroidismo can be caused by copper deposits in the parathyroid glands in patients with Enfermedad de Wilson.<|>6)\n##\n(\"relationship\"<|>GLUCOCORTICOIDES<|>OSTEOPOROSIS<|>Long-term use of glucocorticoids is a major risk factor for developing osteoporosis.<|>8)\n##\n(\"relationship\"<|>OSTEOPOROSIS<|>FRATURA<|>Osteoporosis significantly increases the risk of fractures in affected individuals.<|>9)\n##\n(\"relationship\"<|>DMO<|>OSTEOPOROSIS<|>DMO is used to assess bone density and diagnose osteoporosis.<|>8)\n##\n(\"relationship\"<|>BISFOSFONATOS<|>OSTEOPOROSIS<|>Bisfosfonatos are recommended for the treatment of osteoporosis to reduce fracture risk.<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 17     No se han descrito casos de hipoparatiroidismo como consecuencia de:                                                               COMENTARIO\n              A. La administración de 131I en la enfermedad de Graves.                                                                           La terapia con glucocorticoides es la causa más frecuente de osteoporosis secundaria.\n              B. Depósitos de cobre en la enfermedad de Wilson.                                                                                  Además de tener efectos directos en el osteoblasto y en el osteoclasto, los glucocorticoides\n                                                                                                                                                 inducen también hiperparatiroidismo, hipogonadismo secundario, alteración del metabo-\n              C. Depósitos de glucosa-6-fosfato en la glucogenosis tipo 1.                                                                       lismo de la vitamina D, atrofia muscular e hipercalciuria. Todos estos factores contribuyen\n              D.  Metástasis.                                                                                                                    a una pérdida rápida y continua de hueso, más pronunciado en los primeros meses de\n                                                                                                                                                 tratamiento, por lo que no se debe esperar para iniciar tratamiento o prevenirla.\n              COMENTARIO                                                                                                                         Además, los glucocorticoides aumentan el riesgo de fractura y las fracturas se produ-\n              El hipoparatiroidismo puede ser una complicación infrecuente de la ablación con yodo                                               cen con valores más altos de DMO que en la osteoporosis posmenopáusica. La                                      DMO\n              radiactivo de la glándula tiroidea por enfermedad de Graves-Basedow.                                                               inicial no es un factor predictivo de fracturas                   y puede ser normal a menudo, incluso\n                                                                                                                                                 en presencia de resorción continua y de fracturas recurrentes. El hueso trabecular es el\n              Puede también estar causado por enfermedades infiltrantes de las glándulas paratiroides.                                           más afectado y la DMO vertebral es el indicador más sensible de la pérdida ósea. Los\n              Esto se produce en enfermedades por sobrecarga de hierro, como la hemocromatosis o                                                 marcadores de recambio óseo no son útiles en el tratamiento de estos pacientes.\n              en pacientes con talasemia mayor que han recibido numerosas transfusiones. El depósito                                             El aumento del riesgo de fractura ocurre con dosis de prednisona o su equivalente tan bajo\n              de cobre en la enfermedad de Wilson o las granulomatosis pueden causar también dis-                                                como 2,5 mg/día.\n              función paratiroidea. Las metástasis               paratiroideas pueden provocar hipoparatiroidismo,\n              pero es infrecuente, supuestamente por la necesidad de afectación de las cuatro glándulas                                          La pérdida ósea inducida por glucocorticoides debe tratarse de manera agresiva, especial-\n              antes de que aparezca un hipoparatiroidismo apreciable.                                                                            mente en aquellos que ya tienen un alto riesgo de fractura (edad avanzada, fractura previa\n                                                                                                                                                 por  fragilidad). En otros individuos, el factor            de riesgo clínico      y la evaluación de        la DMO\n              Referencias:                                                                                                                       pueden ayudar a guiar la terapia.\n              • Goltzman D. Hypoparathyroidism. Rosen CJ, ed. UptoDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 10 de\n                junio de 2019).                                                                                                                  La Asociación Americana de Reumatología sugiere que todos los pacientes que toman glu-\n              • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n                                                                                                                                                 cocorticoides (cualquier dosis con una duración prevista de 3 meses o más) deben man-\n                                                                                                                                                 tener una ingesta total de calcio de 1.000 a 1.200 mg y vitamina D de 600 a 800 UI/día a\n     7.3 Osteoporosis                                                                                                                            través de dieta y/o suplementos. Se recomienda además tratamiento con bisfosfonatos en\n                                                                                                                                                 los pacientes con riesgo medio o alto calculado con la herramienta para evaluar el riesgo\n                                                                                                                                                 de fractura (Fracture Risk Assessment Tool, FRAX).\n       18     Mujer de 75 años, con menopausia a los 52 años, sin antecedentes familiares ni                                                     Referencias:\n              personales de fractura, diagnosticada de cuadro inflamatorio, que va a iniciar ya                                                  • Rosen HN. Calcium and vitamin D supplementation in osteoporosis. Rosen CJ, Schmader KE, eds. UptoDate. Waltham, MA:\n                                                                                                                                                   UpToDate Inc. https://www.uptodate.com (acceso 10 de junio de 2019).\n              tratamiento con prednisona a dosis altas y con expectativa de tratamiento durante                                                  • Rosen HN, Drezner MK. Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women. Rosen CJ,\n              al menos un año. La ingesta de calcio con alimentos naturales no alcanza los                                                         Schmader KE, eds. UptoDate. Waltham, MA: UpToDate Inc. https://www\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GOLTZMAN D<|>PERSON<|>Goltzman D is an author referenced in the context of hypoparathyroidism in medical literature.)\n##\n(\"entity\"<|>MELMED S<|>PERSON<|>Melmed S is an author referenced in the context of endocrinology in medical literature.)\n##\n(\"entity\"<|>POLONSKY KS<|>PERSON<|>Polonsky KS is an author referenced in the context of endocrinology in medical literature.)\n##\n(\"entity\"<|>REED LARSEN P<|>PERSON<|>Reed Larsen P is an author referenced in the context of endocrinology in medical literature.)\n##\n(\"entity\"<|>KRONENBERG HM<|>PERSON<|>Kronenberg HM is an author referenced in the context of endocrinology in medical literature.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a medical information provider that publishes clinical guidelines and literature.)\n##\n(\"entity\"<|>ELSEVIER<|>ORGANIZATION<|>Elsevier is a publishing company known for its medical and scientific literature, including textbooks.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is a city in Pennsylvania, USA, known for its medical and scientific institutions, including those associated with Elsevier.)\n##\n(\"entity\"<|>OSTEOPOROSIS<|>EVENT<|>Osteoporosis is a medical condition characterized by weakened bones and increased risk of fractures, often discussed in the context of glucocorticoid treatment.)\n##\n(\"entity\"<|>PREDNISONE<|>EVENT<|>Prednisone is a corticosteroid medication used to treat various conditions, including inflammatory diseases, and is associated with osteoporosis risk.)\n##\n(\"relationship\"<|>GOLTZMAN D<|>UPTODATE INC<|>Goltzman D's work on hypoparathyroidism is published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>MELMED S<|>UPTODATE INC<|>Melmed S's work on endocrinology is published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>POLONSKY KS<|>UPTODATE INC<|>Polonsky KS's work on endocrinology is published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>REED LARSEN P<|>UPTODATE INC<|>Reed Larsen P's work on endocrinology is published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>KRONENBERG HM<|>UPTODATE INC<|>Kronenberg HM's work on endocrinology is published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>MELMED S<|>ELSEVIER<|>Melmed S's work on endocrinology is published by Elsevier.<|>7)\n##\n(\"relationship\"<|>POLONSKY KS<|>ELSEVIER<|>Polonsky KS's work on endocrinology is published by Elsevier.<|>7)\n##\n(\"relationship\"<|>REED LARSEN P<|>ELSEVIER<|>Reed Larsen P's work on endocrinology is published by Elsevier.<|>7)\n##\n(\"relationship\"<|>KRONENBERG HM<|>ELSEVIER<|>Kronenberg HM's work on endocrinology is published by Elsevier.<|>7)\n##\n(\"relationship\"<|>OSTEOPOROSIS<|>PREDNISONE<|>Osteoporosis can be a complication of long-term treatment with prednisone.<|>8)\n<|COMPLETE|>"}]}